Compare Eli Lilly And Co (LLY) vs Marsh & McLennan Companies, Inc. (MRSH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs Marsh & McLennan Companies, Inc. — how do they compare? Eli Lilly And Co trades at $1,177 (market cap $1.04T), while Marsh & McLennan Companies, Inc. trades at $175.94 (market cap $84.31B). The key difference: Eli Lilly And Co is far larger — about 12.3× Marsh & McLennan Companies, Inc.'s market cap, and Marsh & McLennan Companies, Inc. pays the higher dividend (2.24%). Which is the better fit depends on your goals — on Pluang, investors hold Eli Lilly And Co for 93 Days and Marsh & McLennan Companies, Inc. for 109 Days on average.
| LLY | MRSH | |
|---|---|---|
Market Cap | $1.04T | $84.31B |
Volume | 3,064,878 | 3,948,947 |
Sector | Health | Financials |
52-Week High | $1.28K | $207.02 |
52-Week Low | $799.57 | $157.32 |
Typical Hold Time | 93 Days | 109 Days |
Enterprise Value | $1.09T | $104.99B |
Dividend Yield | 0.59% | 2.24% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,176.69, down 1.01% on the day, amid a bullish technical outlook and strong fundamental performance. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $8.38 surpassing the $6.40 consensus. Revenue surged to $65.18B in 2025, driving a net income margin of 33.53%. Recent news highlights promising pipeline developments in weight-loss and diabetes drugs, reinforcing growth prospects.
The outlook remains positive given robust revenue growth, high profitability, and analyst consensus favoring buys. Key risks include elevated valuation multiples and competitive pressures in the pharmaceutical sector. With a consensus price target of $1,350, upside potential exists, but investors should weigh execution risks against the company's innovation pipeline.
MRSH trades at $176.16, up 1.44% today, with a bullish technical signal and consistent earnings beats in recent quarters. The company completed the acquisition of Accel Holdings on October 2, 2026, expanding its advisory footprint. Revenue grew to $27.0B in 2025, with a net income margin of 15.41%, while valuation ratios like P/E of 21.57 and ROE of 25.72% reflect strong profitability. Analysts maintain a consensus price target of $202.71, though sentiment is mixed with a 'Hold' rating from most.
The outlook for MRSH is positive due to earnings momentum and strategic acquisitions, but risks include competitive pressures and potential margin compression. Upside remains if the company meets Q3 2026 EPS expectations of $1.97, supported by solid cash flow trends. Investors should weigh the high P/B ratio of 5.55 against growth prospects in the reinsurance sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About Marsh & McLennan Companies, Inc.
Marsh & McLennan Companies Inc is a professional services firm that provides advice and solutions in the areas of risk, strategy, and human capital. The company operates through two main segments: risk and insurance services and consulting. In risk and insurance services, the firm offers services via Marsh (an insurance broker) and Guy Carpenter (a risk and reinsurance specialist). The consulting division comprises Mercer (a provider of human resource services) and Oliver Wyman (management and economic consultancy).
Read more on MRSH →
